Ai Drug Adverse - Revision history

Wordpad: BloomWiki: Ai Drug Adverse

2026-04-25T01:46:51Z

BloomWiki: Ai Drug Adverse

← Older revision		Revision as of 01:46, 25 April 2026
Line 1:		Line 1:
			<div style="background-color: #4B0082; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
	{{BloomIntro}}		{{BloomIntro}}
	AI for detecting drug adverse effects applies machine learning to pharmacovigilance — the ongoing monitoring of medication safety after drugs reach the market. Clinical trials detect only the most common adverse effects (AEs); rare events affecting 1 in 10,000 patients may take years of post-market use to surface. AI accelerates signal detection by mining electronic health records for unexpected drug-outcome associations, analyzing social media and patient forums for reported side effects, processing spontaneous report databases (FDA FAERS), and predicting which drugs are likely to cause AEs before they are marketed. This is a critical safety function: many drugs withdrawn from market (Vioxx, thalidomide) caused harm that better surveillance might have detected sooner.		AI for detecting drug adverse effects applies machine learning to pharmacovigilance — the ongoing monitoring of medication safety after drugs reach the market. Clinical trials detect only the most common adverse effects (AEs); rare events affecting 1 in 10,000 patients may take years of post-market use to surface. AI accelerates signal detection by mining electronic health records for unexpected drug-outcome associations, analyzing social media and patient forums for reported side effects, processing spontaneous report databases (FDA FAERS), and predicting which drugs are likely to cause AEs before they are marketed. This is a critical safety function: many drugs withdrawn from market (Vioxx, thalidomide) caused harm that better surveillance might have detected sooner.
			</div>

	== Remembering ==		__TOC__

			<div style="background-color: #000080; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Remembering</span> ==
	* '''Pharmacovigilance''' — The science of monitoring, detecting, assessing, and preventing adverse effects of medicines.		* '''Pharmacovigilance''' — The science of monitoring, detecting, assessing, and preventing adverse effects of medicines.
	* '''Adverse drug event (ADE)''' — Harm to a patient resulting from medical use of a drug; includes adverse reactions, medication errors, overdoses.		* '''Adverse drug event (ADE)''' — Harm to a patient resulting from medical use of a drug; includes adverse reactions, medication errors, overdoses.
Line 17:		Line 22:
	* '''Drug-drug interaction (DDI)''' — Adverse interaction between two co-administered drugs; ML predicts DDIs from molecular and clinical data.		* '''Drug-drug interaction (DDI)''' — Adverse interaction between two co-administered drugs; ML predicts DDIs from molecular and clinical data.
	* '''MedDRA''' — Medical Dictionary for Regulatory Activities; standard terminology for classifying ADEs.		* '''MedDRA''' — Medical Dictionary for Regulatory Activities; standard terminology for classifying ADEs.
			</div>

	== Understanding ==		<div style="background-color: #006400; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Understanding</span> ==
	Pharmacovigilance faces three core data challenges:		Pharmacovigilance faces three core data challenges:
	# '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias;		# '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias;
Line 35:		Line 42:

	'''Computational DDI prediction''': With thousands of approved drugs and millions of possible pairs, experimental testing of all drug-drug interactions is impossible. ML models predict DDI risk from: drug molecular features, protein binding profiles, pharmacokinetic parameters, and known interaction databases (DrugBank, STITCH). Graph neural networks on drug-protein interaction networks achieve AUC >0.9 for DDI prediction.		'''Computational DDI prediction''': With thousands of approved drugs and millions of possible pairs, experimental testing of all drug-drug interactions is impossible. ML models predict DDI risk from: drug molecular features, protein binding profiles, pharmacokinetic parameters, and known interaction databases (DrugBank, STITCH). Graph neural networks on drug-protein interaction networks achieve AUC >0.9 for DDI prediction.
			</div>

	== Applying ==		<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Applying</span> ==
	'''NLP extraction of adverse drug events from clinical notes:'''		'''NLP extraction of adverse drug events from clinical notes:'''
	<syntaxhighlight lang="python">		<syntaxhighlight lang="python">
Line 102:		Line 111:
	: '''DDI prediction''' → DDIMDL, SSI-DDI (graph learning), DrugBank + ML		: '''DDI prediction''' → DDIMDL, SSI-DDI (graph learning), DrugBank + ML
	: '''Social media''' → Social Media Mining for Health (SMM4H), MedWatcher		: '''Social media''' → Social Media Mining for Health (SMM4H), MedWatcher
			</div>

	== Analyzing ==		<div style="background-color: #8B4500; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Analyzing</span> ==
	{\| class="wikitable"		{\| class="wikitable"
	\|+ Pharmacovigilance Signal Detection Methods		\|+ Pharmacovigilance Signal Detection Methods
Line 122:		Line 133:

	'''Failure modes''': Notoriety bias — high-media-coverage drugs generate more reports regardless of true ADR rate. Indication confounding — patients taking drug X for condition Y; outcome Y attributed to drug X. Weber effect — spontaneous reporting spikes in years 1-2 post-launch, then declines, creating spurious temporal trends. Social media noise — most drug-related posts don't contain genuine ADE reports. NLP coding errors — mapping free text to MedDRA can introduce systematic errors.		'''Failure modes''': Notoriety bias — high-media-coverage drugs generate more reports regardless of true ADR rate. Indication confounding — patients taking drug X for condition Y; outcome Y attributed to drug X. Weber effect — spontaneous reporting spikes in years 1-2 post-launch, then declines, creating spurious temporal trends. Social media noise — most drug-related posts don't contain genuine ADE reports. NLP coding errors — mapping free text to MedDRA can introduce systematic errors.
			</div>

	== Evaluating ==		<div style="background-color: #483D8B; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Evaluating</span> ==
	Drug safety AI evaluation:		Drug safety AI evaluation:
	# '''Known ADE recovery''': test whether method detects known drug-ADE pairs that were withdrawn from market or added to labels; calculate sensitivity/specificity.		# '''Known ADE recovery''': test whether method detects known drug-ADE pairs that were withdrawn from market or added to labels; calculate sensitivity/specificity.
Line 130:		Line 143:
	# '''NLP accuracy''': precision/recall for drug and ADE entity extraction against manually annotated clinical notes.		# '''NLP accuracy''': precision/recall for drug and ADE entity extraction against manually annotated clinical notes.
	# '''Cross-system agreement''': do signals from FAERS analysis agree with EHR-based signals for the same drug?		# '''Cross-system agreement''': do signals from FAERS analysis agree with EHR-based signals for the same drug?
			</div>

	== Creating ==		<div style="background-color: #2F4F4F; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Creating</span> ==
	Building a pharmacovigilance AI system:		Building a pharmacovigilance AI system:
	# Data: download FAERS quarterly files + EHR data if available + social media stream.		# Data: download FAERS quarterly files + EHR data if available + social media stream.
Line 143:		Line 158:
	[[Category:Pharmacovigilance]]		[[Category:Pharmacovigilance]]
	[[Category:Drug Safety]]		[[Category:Drug Safety]]
			</div>

Wordpad: BloomWiki: Ai Drug Adverse

2026-04-23T14:36:29Z

BloomWiki: Ai Drug Adverse

← Older revision		Revision as of 14:36, 23 April 2026
Line 19:		Line 19:

	== Understanding ==		== Understanding ==
	Pharmacovigilance faces three core data challenges: ~~(1)~~ '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias; ~~(2)~~ '''data heterogeneity''' — reports use inconsistent terminology, varying detail levels, and multiple languages; ~~(3)~~ '''confounding''' — patients taking a drug may have the disease that caused the adverse event, making causal attribution difficult.		Pharmacovigilance faces three core data challenges:
			# '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias;
			# '''data heterogeneity''' — reports use inconsistent terminology, varying detail levels, and multiple languages;
			# '''confounding''' — patients taking a drug may have the disease that caused the adverse event, making causal attribution difficult.

	'''EHR mining for ADE detection''': Large EHR databases (CPRD in UK, Optum in US, VA CDW) contain millions of patient records with drug prescriptions and outcome data. ML and pharmacoepidemiology methods (self-controlled case series, prescription sequence symmetry analysis) detect unexpected drug-outcome associations. Stanford's PURPLE and FDA's Sentinel System apply these approaches systematically.		'''EHR mining for ADE detection''': Large EHR databases (CPRD in UK, Optum in US, VA CDW) contain millions of patient records with drug prescriptions and outcome data. ML and pharmacoepidemiology methods (self-controlled case series, prescription sequence symmetry analysis) detect unexpected drug-outcome associations. Stanford's PURPLE and FDA's Sentinel System apply these approaches systematically.

	'''NLP for spontaneous report processing''': FDA FAERS receives thousands of reports daily as unstructured text. NLP pipelines extract structured drug-ADE pairs: ~~(1)~~ entity recognition identifies drugs and medical concepts; ~~(2)~~ relation extraction identifies which drug caused which event; ~~(3)~~ negation handling distinguishes "developed rash" from "no rash developed"; ~~(4)~~ MedDRA coding maps free text to standard terminology. FDA's ARIA project and academic systems automate FAERS processing.		'''NLP for spontaneous report processing''': FDA FAERS receives thousands of reports daily as unstructured text. NLP pipelines extract structured drug-ADE pairs:
			# entity recognition identifies drugs and medical concepts;
			# relation extraction identifies which drug caused which event;
			# negation handling distinguishes "developed rash" from "no rash developed";
			# MedDRA coding maps free text to standard terminology. FDA's ARIA project and academic systems automate FAERS processing.

	'''Social media signal detection''': Patients discuss medication side effects on Twitter, Reddit (/r/medication, /r/askdocs), DailyStrength, and PatientsLikeMe before reporting to FAERS. NLP analysis of these discussions can surface signals earlier. Challenges: slang ("pilled", "brain zaps" for SSRI discontinuation), spam, and high noise ratio. Studies show social media signals precede FAERS signals by 3–6 months for some drugs.		'''Social media signal detection''': Patients discuss medication side effects on Twitter, Reddit (/r/medication, /r/askdocs), DailyStrength, and PatientsLikeMe before reporting to FAERS. NLP analysis of these discussions can surface signals earlier. Challenges: slang ("pilled", "brain zaps" for SSRI discontinuation), spam, and high noise ratio. Studies show social media signals precede FAERS signals by 3–6 months for some drugs.
Line 117:		Line 124:

	== Evaluating ==		== Evaluating ==
	Drug safety AI evaluation: ~~(1)~~ '''Known ADE recovery''': test whether method detects known drug-ADE pairs that were withdrawn from market or added to labels; calculate sensitivity/specificity. ~~(2)~~ '''PPV at alert threshold''': of signals flagged, what fraction represent true signals confirmed by subsequent investigation? ~~(3)~~ '''Time-to-signal''': how many months before official label change or FAERS signal did method first detect? ~~(4)~~ '''NLP accuracy''': precision/recall for drug and ADE entity extraction against manually annotated clinical notes. ~~(5)~~ '''Cross-system agreement''': do signals from FAERS analysis agree with EHR-based signals for the same drug?		Drug safety AI evaluation:
			# '''Known ADE recovery''': test whether method detects known drug-ADE pairs that were withdrawn from market or added to labels; calculate sensitivity/specificity.
			# '''PPV at alert threshold''': of signals flagged, what fraction represent true signals confirmed by subsequent investigation?
			# '''Time-to-signal''': how many months before official label change or FAERS signal did method first detect?
			# '''NLP accuracy''': precision/recall for drug and ADE entity extraction against manually annotated clinical notes.
			# '''Cross-system agreement''': do signals from FAERS analysis agree with EHR-based signals for the same drug?

	== Creating ==		== Creating ==
	Building a pharmacovigilance AI system: ~~(1)~~ Data: download FAERS quarterly files + EHR data if available + social media stream. ~~(2)~~ NLP pipeline: extract drug-ADE pairs from all text sources; MedDRA code mapping; deduplicate. ~~(3)~~ Signal detection: apply disproportionality (ROR, PRR) weekly on FAERS; SCCS on EHR data quarterly. ~~(4)~~ Alert ranking: prioritize signals by: strength (ROR + 95% CI), clinical seriousness (death, hospitalization), novelty (not in current label). ~~(5)~~ Signal validation: pharmacist/pharmacologist reviews top signals; literature search; regulatory decision. ~~(6)~~ Reporting: submit validated new signals to FDA MedWatch; update internal drug safety database.		Building a pharmacovigilance AI system:
			# Data: download FAERS quarterly files + EHR data if available + social media stream.
			# NLP pipeline: extract drug-ADE pairs from all text sources; MedDRA code mapping; deduplicate.
			# Signal detection: apply disproportionality (ROR, PRR) weekly on FAERS; SCCS on EHR data quarterly.
			# Alert ranking: prioritize signals by: strength (ROR + 95% CI), clinical seriousness (death, hospitalization), novelty (not in current label).
			# Signal validation: pharmacist/pharmacologist reviews top signals; literature search; regulatory decision.
			# Reporting: submit validated new signals to FDA MedWatch; update internal drug safety database.

	[[Category:Artificial Intelligence]]		[[Category:Artificial Intelligence]]
	[[Category:Pharmacovigilance]]		[[Category:Pharmacovigilance]]
	[[Category:Drug Safety]]		[[Category:Drug Safety]]

Wordpad: BloomWiki: Ai Drug Adverse

2026-04-23T14:21:13Z

BloomWiki: Ai Drug Adverse

New page

{{BloomIntro}}
AI for detecting drug adverse effects applies machine learning to pharmacovigilance — the ongoing monitoring of medication safety after drugs reach the market. Clinical trials detect only the most common adverse effects (AEs); rare events affecting 1 in 10,000 patients may take years of post-market use to surface. AI accelerates signal detection by mining electronic health records for unexpected drug-outcome associations, analyzing social media and patient forums for reported side effects, processing spontaneous report databases (FDA FAERS), and predicting which drugs are likely to cause AEs before they are marketed. This is a critical safety function: many drugs withdrawn from market (Vioxx, thalidomide) caused harm that better surveillance might have detected sooner.

== Remembering ==
* '''Pharmacovigilance''' — The science of monitoring, detecting, assessing, and preventing adverse effects of medicines.
* '''Adverse drug event (ADE)''' — Harm to a patient resulting from medical use of a drug; includes adverse reactions, medication errors, overdoses.
* '''Adverse drug reaction (ADR)''' — Harmful, unintended response to a drug at normal doses; a subset of ADEs.
* '''FAERS (FDA Adverse Event Reporting System)''' — US FDA's spontaneous reporting database; 20M+ reports; publicly accessible.
* '''EudraVigilance''' — European Medicines Agency equivalent of FAERS; used for EU drug safety monitoring.
* '''Spontaneous reporting''' — Voluntary reporting of suspected adverse reactions by healthcare professionals and patients.
* '''Disproportionality analysis''' — Statistical method detecting drug-event pairs reported more often than expected by chance in spontaneous reports.
* '''Reporting odds ratio (ROR)''' — A disproportionality statistic: ROR > 1 suggests drug-event association in spontaneous reports.
* '''Information component (IC)''' — A Bayesian disproportionality measure used by WHO for signal detection.
* '''NLP for pharmacovigilance''' — Extracting ADE reports from unstructured text: clinical notes, social media, scientific literature.
* '''Social media pharmacovigilance''' — Monitoring Twitter, Reddit, health forums for drug side effect mentions.
* '''Drug repurposing signal''' — Unexpected beneficial effects discovered through pharmacovigilance data.
* '''Drug-drug interaction (DDI)''' — Adverse interaction between two co-administered drugs; ML predicts DDIs from molecular and clinical data.
* '''MedDRA''' — Medical Dictionary for Regulatory Activities; standard terminology for classifying ADEs.

== Understanding ==
Pharmacovigilance faces three core data challenges: (1) '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias; (2) '''data heterogeneity''' — reports use inconsistent terminology, varying detail levels, and multiple languages; (3) '''confounding''' — patients taking a drug may have the disease that caused the adverse event, making causal attribution difficult.

'''EHR mining for ADE detection''': Large EHR databases (CPRD in UK, Optum in US, VA CDW) contain millions of patient records with drug prescriptions and outcome data. ML and pharmacoepidemiology methods (self-controlled case series, prescription sequence symmetry analysis) detect unexpected drug-outcome associations. Stanford's PURPLE and FDA's Sentinel System apply these approaches systematically.

'''NLP for spontaneous report processing''': FDA FAERS receives thousands of reports daily as unstructured text. NLP pipelines extract structured drug-ADE pairs: (1) entity recognition identifies drugs and medical concepts; (2) relation extraction identifies which drug caused which event; (3) negation handling distinguishes "developed rash" from "no rash developed"; (4) MedDRA coding maps free text to standard terminology. FDA's ARIA project and academic systems automate FAERS processing.

'''Social media signal detection''': Patients discuss medication side effects on Twitter, Reddit (/r/medication, /r/askdocs), DailyStrength, and PatientsLikeMe before reporting to FAERS. NLP analysis of these discussions can surface signals earlier. Challenges: slang ("pilled", "brain zaps" for SSRI discontinuation), spam, and high noise ratio. Studies show social media signals precede FAERS signals by 3–6 months for some drugs.

'''Computational DDI prediction''': With thousands of approved drugs and millions of possible pairs, experimental testing of all drug-drug interactions is impossible. ML models predict DDI risk from: drug molecular features, protein binding profiles, pharmacokinetic parameters, and known interaction databases (DrugBank, STITCH). Graph neural networks on drug-protein interaction networks achieve AUC >0.9 for DDI prediction.

== Applying ==
'''NLP extraction of adverse drug events from clinical notes:'''
<syntaxhighlight lang="python">
from transformers import pipeline, AutoTokenizer, AutoModelForTokenClassification
import re

# BioBERT fine-tuned for ADE detection (NER on clinical text)
model_name = "allenai/biomed_roberta_base" # or "d4data/biomedical-ner-all"
ner_pipeline = pipeline("ner", model="allenai/biomed_roberta_base",
aggregation_strategy="simple")

# ADE-specific NER model (trained on ADE corpus)
ade_model = AutoModelForTokenClassification.from_pretrained(
"ncats/DrugProt-bioBERT-base-cased" # Drug + protein NER
)

def extract_drug_ade_pairs(clinical_note: str) -> list[dict]:
"""Extract (drug, adverse_effect) pairs from clinical text."""
entities = ner_pipeline(clinical_note)
drugs, adverse_effects = [], []
for ent in entities:
if ent['entity_group'] in ['DRUG', 'CHEMICAL']:
drugs.append({'text': ent['word'], 'start': ent['start'], 'end': ent['end']})
elif ent['entity_group'] in ['DISEASE', 'SYMPTOM', 'ADE']:
adverse_effects.append({'text': ent['word'], 'start': ent['start']})
# Simple proximity-based relation extraction: drug + ADE within same sentence
pairs = []
sentences = clinical_note.split('.')
for sent in sentences:
sent_drugs = [d for d in drugs if d['text'].lower() in sent.lower()]
sent_aes = [a for a in adverse_effects if a['text'].lower() in sent.lower()]
for drug in sent_drugs:
for ae in sent_aes:
pairs.append({
'drug': drug['text'],
'adverse_effect': ae['text'],
'sentence': sent.strip()
})
return pairs

# Disproportionality analysis on FAERS data
import pandas as pd
import numpy as np

def reporting_odds_ratio(faers_df: pd.DataFrame, drug: str, event: str) -> dict:
"""Compute ROR for drug-event pair in spontaneous reports."""
a = len(faers_df[(faers_df['drug'] == drug) & (faers_df['event'] == event)])
b = len(faers_df[(faers_df['drug'] == drug) & (faers_df['event'] != event)])
c = len(faers_df[(faers_df['drug'] != drug) & (faers_df['event'] == event)])
d = len(faers_df[(faers_df['drug'] != drug) & (faers_df['event'] != event)])
if b == 0 or c == 0: return {'ror': None, 'signal': False}
ror = (a * d) / (b * c)
# 95% CI on log scale
se = np.sqrt(1/a + 1/b + 1/c + 1/d)
ci_low = np.exp(np.log(ror) - 1.96 * se)
ci_high = np.exp(np.log(ror) + 1.96 * se)
signal = ror > 2.0 and ci_low > 1.0 and a >= 3 # Standard signal threshold
return {'ror': ror, 'ci': (ci_low, ci_high), 'n': a, 'signal': signal}
</syntaxhighlight>

; Drug safety AI tools
: '''FAERS analysis''' → OpenVigil (web), FDA Sentinel System, WHO VigiBase / VigiAccess
: '''EHR pharmacovigilance''' → CPRD Aurum + SCCS, Optum ClinicalAI, FDA MedWatch
: '''NLP ADE extraction''' → MedEx, cTAKES, clinicalBERT NER models
: '''DDI prediction''' → DDIMDL, SSI-DDI (graph learning), DrugBank + ML
: '''Social media''' → Social Media Mining for Health (SMM4H), MedWatcher

== Analyzing ==
{| class="wikitable"
|+ Pharmacovigilance Signal Detection Methods
! Method !! Data Source !! Signal Speed !! Causal Evidence Strength
|-
| Disproportionality (ROR, IC) || Spontaneous reports || Months || Weak (association only)
|-
| SCCS (self-controlled) || EHR || Months || Moderate (controls confounding)
|-
| CPRD prescription sequence || EHR || Months-years || Moderate
|-
| NLP from social media || Twitter, Reddit || Weeks || Weak (unverified)
|-
| NLP from clinical notes || Hospital EHR || Months || Moderate
|-
| ML DDI prediction || Molecular data || Pre-market || Moderate (in silico)
|}

'''Failure modes''': Notoriety bias — high-media-coverage drugs generate more reports regardless of true ADR rate. Indication confounding — patients taking drug X for condition Y; outcome Y attributed to drug X. Weber effect — spontaneous reporting spikes in years 1-2 post-launch, then declines, creating spurious temporal trends. Social media noise — most drug-related posts don't contain genuine ADE reports. NLP coding errors — mapping free text to MedDRA can introduce systematic errors.

== Evaluating ==
Drug safety AI evaluation: (1) '''Known ADE recovery''': test whether method detects known drug-ADE pairs that were withdrawn from market or added to labels; calculate sensitivity/specificity. (2) '''PPV at alert threshold''': of signals flagged, what fraction represent true signals confirmed by subsequent investigation? (3) '''Time-to-signal''': how many months before official label change or FAERS signal did method first detect? (4) '''NLP accuracy''': precision/recall for drug and ADE entity extraction against manually annotated clinical notes. (5) '''Cross-system agreement''': do signals from FAERS analysis agree with EHR-based signals for the same drug?

== Creating ==
Building a pharmacovigilance AI system: (1) Data: download FAERS quarterly files + EHR data if available + social media stream. (2) NLP pipeline: extract drug-ADE pairs from all text sources; MedDRA code mapping; deduplicate. (3) Signal detection: apply disproportionality (ROR, PRR) weekly on FAERS; SCCS on EHR data quarterly. (4) Alert ranking: prioritize signals by: strength (ROR + 95% CI), clinical seriousness (death, hospitalization), novelty (not in current label). (5) Signal validation: pharmacist/pharmacologist reviews top signals; literature search; regulatory decision. (6) Reporting: submit validated new signals to FDA MedWatch; update internal drug safety database.

[[Category:Artificial Intelligence]]
[[Category:Pharmacovigilance]]
[[Category:Drug Safety]]